TP53 and neoplasm: One of the most well-characterized is AZD1775, a potent and highly selective WEE1i that has shown anti-tumor effects, independent of p53 mutational status, in various in vitro and in vivo cancer models as a single-agent or in combination with chemotherapy or IR [221,222].